NZ741606A - Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency - Google Patents
Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiencyInfo
- Publication number
- NZ741606A NZ741606A NZ74160613A NZ74160613A NZ741606A NZ 741606 A NZ741606 A NZ 741606A NZ 74160613 A NZ74160613 A NZ 74160613A NZ 74160613 A NZ74160613 A NZ 74160613A NZ 741606 A NZ741606 A NZ 741606A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cis
- retinyl
- subject
- therapeutic dose
- synthetic retinal
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is the use of a synthetic retinal derivative in the manufacture of a medicament for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal, wherein the medicament is administered to the subject according to the following dosing schedule: (a) administering a first therapeutic dose of a synthetic retinal derivative to a subject in need thereof, wherein the first therapeutic dose is administered as a divided dose over a period of from about 2 to about 7 days; (b) providing a resting period of from about 7 to about 28 days; and (c) administering a second therapeutic dose of the synthetic retinal derivative to said subject following the end of the resting period, wherein said subject demonstrates a decline in visual function prior to administration of the second therapeutic dose, and wherein the synthetic retinal derivative is a 9-cis-retinyl ester or a 11-cis-retinyl ester which is selected respectively from 9-cis-retinyl acetate or 9-cis-retinyl succinate or from 11-cis-retinyl acetate, 11-cis-retinyl succinate, 11-cis-retinyl citrate, 11-cis-retinyl ketoglutarate, 11-cis-retinyl fumarate, 11-cis-retinyl malate or 11-cis-retinyl oxaloacetate, or the synthetic retinal derivative may be selected from 9-cis retinal, 11-cis-retinal, 9-cis-retinol, or 11-cis-retinol.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261605729P | 2012-03-01 | 2012-03-01 | |
| US201261642212P | 2012-05-03 | 2012-05-03 | |
| US201261644360P | 2012-05-08 | 2012-05-08 | |
| NZ72491013 | 2013-03-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ741606A true NZ741606A (en) | 2019-10-25 |
Family
ID=68318671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ74160613A NZ741606A (en) | 2012-03-01 | 2013-03-01 | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
Country Status (1)
| Country | Link |
|---|---|
| NZ (1) | NZ741606A (en) |
-
2013
- 2013-03-01 NZ NZ74160613A patent/NZ741606A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629267A (en) | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency | |
| PH12021550328A1 (en) | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject | |
| ZA202110659B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| EP4299093A3 (en) | Wearable automatic injection device for controlled administration of therapeutic agents | |
| WO2014004861A3 (en) | Methods of treating pediatric metabolic syndrome | |
| MX2011008448A (en) | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia. | |
| MX350666B (en) | Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia. | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| RU2016106829A (en) | The use of acetyl CoA carboxylase inhibitors for the treatment of acne vulgaris | |
| WO2014107730A3 (en) | Use of fatty acid niacin conjugates for treating diseases | |
| MX2015015036A (en) | Methods for improving lipid profiles using atrasentan. | |
| WO2013155528A3 (en) | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels | |
| MX348418B (en) | Ocular composition containing bromfenac with increased bioavailability. | |
| PH12016500142A1 (en) | Vesicles | |
| MX2015016750A (en) | Immunogenic composition for use in therapy. | |
| WO2009111688A3 (en) | All-trans retinoid esters as active pharmaceutical ingredients, oral and topical dosage form compositions thereof, and methods of treating skin conditions thereof | |
| MX359672B (en) | Methods for chronic pain management and treatment using hcg. | |
| NZ603331A (en) | Therapeutic regimens and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency | |
| BR112015003733A2 (en) | extended release compositions of an aminoalkyl nitrate | |
| NZ741606A (en) | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency | |
| NZ604009A (en) | A combination composition comprising ibuprofen and paracetamol | |
| RU2012129115A (en) | METHOD FOR TREATING ACUTE POST-PERMANENT ENDOMETRITIS IN COWS | |
| PH12021500016A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| MX2015008676A (en) | Metadichol r liquid and gel nanoparticle formulations. | |
| MX2022015602A (en) | Methods of treating visual disorders using daily low dosing of a retinoid compound. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: RETINAGENIX, LLC, US Effective date: 20190329 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAR 2020 BY SHELSTON IP PTY LTD Effective date: 20200128 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY CPA GLOBAL Effective date: 20200227 |
|
| ASS | Change of ownership |
Owner name: RETINAGENIX THERAPEUTICS, INC., US Effective date: 20210120 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY CPA GLOBAL Effective date: 20210305 |
|
| ASS | Change of ownership |
Owner name: RETINAGENIX HOLDING, US Effective date: 20211020 |
|
| LAPS | Patent lapsed |